PM&R Meeting Abstracts

Official abstracts site for the AAPM&R Annual Assembly and the PM&R Journal.

MENU 
  • Home
  • Meetings Archive
    • AAPM&R Annual Assembly 2022
    • AAPM&R Annual Assembly 2021
    • AAPM&R Annual Assembly 2020
    • AAPM&R Annual Assembly 2019
  • Resources
  • Advanced Search

Accelerated Ziconotide Toxicity with Concomitant SSRI Use in a Chronic Back Pain Patient: A Case Report

Michael D. Smith, DO (UPMC Medical Education PM&R Program, Pittsburgh, Pennsylvania)

Meeting: AAPM&R Annual Assembly 2020

Categories: Pain and Spine Medicine (2020)

Session Information

Session Title: Virtual Poster Hall

Session Time: None. Available on demand.

Disclosures: Michael D. Smith, DO: No financial relationships or conflicts of interest

Case Description: Our patient, a 68 year-old-female has a long standing history of depression which has been managed with fluoxetine 80mg daily. She recently underwent and tolerated an intrathecal pump placement with ziconotide infusion for her chronic low back pain. A standard and guideline driven protocol for initial infusion rate and titration schedule was prescribed to reach a therapeutic dose. On the 7th day of her titration schedule, she presented with confusion, generalized weakness, and most notably, nystagmus on exam.

Setting: A community adult hospital.

Patient: A 68 year-old-female with 8-year history of chronic low back pain. Assessment/

Results: The infusion scheduled included an initial ziconotide rate of 2.4mcg/day, with an increase of 1.2mcg/day over a two week period with a max dose of 19.2mcg/day. On the 7th day of her titration schedule she presented to our emergency room and admitted for further work-up. The pump was interrogated which showed no malfunction and the infusion rate was decreased to the minimum with subsequent spontaneously resolved her symptoms.

Discussion: Ziconotide, a non-opioid calcium channel blocker, is a synthetic form of a marine snail conotoxin. It is indicated and approved for the treatment of chronic severe back pain. The drug is characterized by a narrow therapeutic window and must be carefully titrated. Concomitant drugs such as antidepressants and anticonvulsants may accelerate the risk for side effects observed with ziconotide as seen with our patient who was taking fluoxetine for depression.

Conclusion: This case outlines the need for more conservative and slower ziconotide titration schedules than guidelines recommend in individuals taking antidepressants, such as fluoxetine.

Level of Evidence: Level V

To cite this abstract in AMA style:

Smith MD. Accelerated Ziconotide Toxicity with Concomitant SSRI Use in a Chronic Back Pain Patient: A Case Report [abstract]. PM R. 2020; 12(S1)(suppl 1). https://pmrjabstracts.org/abstract/accelerated-ziconotide-toxicity-with-concomitant-ssri-use-in-a-chronic-back-pain-patient-a-case-report/. Accessed May 8, 2025.
  • Tweet
  • Email
  • Print

« Back to AAPM&R Annual Assembly 2020

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/accelerated-ziconotide-toxicity-with-concomitant-ssri-use-in-a-chronic-back-pain-patient-a-case-report/

Leading the Way. Baltimore, MD & Virtual. October 20-23, 2022. #aapmr22

PM&R Journal

View issues of PM&R on the Wiley Online Library »

American Academy of Physical Medicine and Rehabilitation

Visit the official site for the American Academy of Physical Medicine and Rehabilitation »

AAPM&R Annual Assembly

Visit the official site for the AAPM&R Annual Assembly »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
Wiley